 DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biotechnology company, today announced the closing of its previously announced underwritten public offering of an aggregate of 2,125,000 shares of its voting common shares at a public offering price of 4.00 per share. 